JPWO2023008553A5 - - Google Patents

Info

Publication number
JPWO2023008553A5
JPWO2023008553A5 JP2023538636A JP2023538636A JPWO2023008553A5 JP WO2023008553 A5 JPWO2023008553 A5 JP WO2023008553A5 JP 2023538636 A JP2023538636 A JP 2023538636A JP 2023538636 A JP2023538636 A JP 2023538636A JP WO2023008553 A5 JPWO2023008553 A5 JP WO2023008553A5
Authority
JP
Japan
Prior art keywords
chicken antibody
coronavirus
ace2
mutant
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023538636A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023008553A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/029274 external-priority patent/WO2023008553A1/ja
Publication of JPWO2023008553A1 publication Critical patent/JPWO2023008553A1/ja
Publication of JPWO2023008553A5 publication Critical patent/JPWO2023008553A5/ja
Pending legal-status Critical Current

Links

JP2023538636A 2021-07-30 2022-07-29 Pending JPWO2023008553A1 (https=)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021125338 2021-07-30
JP2021200190 2021-12-09
JP2022024653 2022-02-21
PCT/JP2022/029274 WO2023008553A1 (ja) 2021-07-30 2022-07-29 変異型コロナウイルスに対するニワトリ抗体

Publications (2)

Publication Number Publication Date
JPWO2023008553A1 JPWO2023008553A1 (https=) 2023-02-02
JPWO2023008553A5 true JPWO2023008553A5 (https=) 2025-08-06

Family

ID=85086077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538636A Pending JPWO2023008553A1 (https=) 2021-07-30 2022-07-29

Country Status (2)

Country Link
JP (1) JPWO2023008553A1 (https=)
WO (1) WO2023008553A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119563028A (zh) * 2022-05-12 2025-03-04 尚威天成信使核糖核酸治疗公司 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
EP4687969A1 (en) * 2023-04-05 2026-02-11 DIOSynVax Ltd Coronavirus vaccines inducing broad immunity against variants
WO2024235231A1 (en) * 2023-05-15 2024-11-21 Providence Therapeutics Holdings Inc. Compositions and methods for the prevention and/or treatment of covid-19
CN117821482B (zh) 2024-03-05 2024-06-18 中国人民解放军军事科学院军事医学研究院 一种编码猴痘病毒和新冠病毒融合抗原的mRNA疫苗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112175074A (zh) * 2020-10-09 2021-01-05 梁永明 基于基因重组抗Covid-19和其他冠状病毒IgY抗体及其他小分子抗体产业化应用

Similar Documents

Publication Publication Date Title
JPWO2023008553A5 (https=)
Choi et al. Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke
Crespo et al. Melatonin limits the expression of profibrogenic genes and ameliorates the progression of hepatic fibrosis in mice
Rogers et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women
JP2009537143A5 (https=)
MX2022012685A (es) Compuestos específicos contra la proteína s de coronavirus y usos de los mismos.
Pera et al. Influence of chemical and ischemic preconditioning on cytokine expression after focal brain ischemia
Wang et al. Impaired spatial learning memory after isoflurane anesthesia or appendectomy in aged mice is associated with microglia activation
Kamio et al. Statins inhibit matrix metalloproteinase release from human lung fibroblasts
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
Martin-Chouly et al. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors
Cosgrove et al. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
Raghavan et al. Histamine potentiates SARS-CoV-2 spike protein entry into endothelial cells
Takamatsu et al. Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy
Koitka et al. Angiotensin converting enzyme 2 in the kidney
WO2023059900A3 (en) Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof
Sha et al. Infection routes, invasion mechanisms, and drug inhibition pathways of human coronaviruses on the nervous system
Raciti et al. Neurological complications of COVID-19: from pathophysiology to rehabilitation. An overview
BRPI0504758A (pt) miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença
Bajire et al. Synergistic effects of COVID-19 and Pseudomonas aeruginosa in chronic obstructive pulmonary disease: a polymicrobial perspective
Papasavas et al. Prediction of postoperative gas bloating after laparoscopic antireflux procedures based on 24-h pH acid reflux pattern
DE60336063D1 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
Küsters et al. Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells
ATE450293T1 (de) Verwendung von molkenpermeat zur behandlung des metabolischen syndroms